Doses of chemotherapeutic agents are limited by various toxicities. Combined therapies with different mechanisms may be a more effective approach to improve the outcome of chemotherapy and bring survival benefit. Anticancer effects induced by various chemotherapeutic agents are considered to be based on induction of apoptosis and are mediated through a final common pathway; activation of caspase-3 and subsequent DNA fragmentation. [1] [2] [3] [4] With the aim of enhancing chemotherapeutic agent-induced apoptosis, we have focused on the function of the apoptosis-promoting gene, Bax. It has been reported that Bax induction alone induces apoptosis in Jurkat cells, 5) which have a Bax gene mutation. 6) Strobel et al. have reported that Bax overexpression enhances apoptosis induced by paclitaxel, vincristine and doxorubicin, but not by carboplatin, etoposide or hydroxyurea in ovarian cancer cells. 7) Wagener et al. have reported that Bax induction alone does not induce apoptosis of breast cancer cells, but sensitizes the cells to epirubicin-induced apoptosis. 8) We have shown that Bax overexpression sensitizes K562 erythroid leukemia cells to apoptosis induced by β-D-arabinofuranoside, doxorubicin, and SN-38 (irinotecan), but not to etoposide. 9) These findings suggest that the effects of Bax overexpression to induce apoptosis and to enhance chemotherapeutic agent-induced apoptosis are different among different cell lines and chemotherapeutic agents.
Patients with advanced colorectal cancer are often treated with 5-fluorouracil-based regimens; however, the responses are partial and no survival benefit has been demonstrated. 10) Mutation of the tumor suppressor gene p53 is frequent in colon cancer cells, 11) and in a clinical treatment of lung cancer, wild-type p53 gene delivery to cancer cells has been performed. 12) Bax gene is considered to be one of the downstream genes regulated by p53, and the promoter of Bax has a p53 binding domain. 13) Bax gene mutation has been reported in hereditary non-polyposis colorectal cancer, but not in other types of colorectal cancer. [14] [15] [16] In addition, there is no report about the sensitization of colon cancer cells to chemotherapeutic agents by Bax overexpression. In the present study, we examined whether Bax induction alone initiates apoptosis in DLD-1 colon cancer cells and whether Bax overexpression sensitizes DLD-1 colon cancer cells to apoptosis induced by chemotherapeutic agents, 5-fluorouracil, mitomycin C, paclitaxel, doxorubicin, and cisplatin.
MATERIALS AND METHODS
Cell culture DLD-1 cells were obtained from the American Type Culture Collection (Rockville, MD), and were maintained in RPMI-1640 medium supplemented with 10% Tet-system approved fetal calf serum (Clontech, Palo Alto, CA) under air containing 5% CO 2 in an incubator at 37°C. DNA transfection pTet-On regulator plasmid (pTet-On) 17) and pTRE response plasmid (pTRE) 18) were purchased from Clontech. Bax gene was inserted to the EcoRI cloning site of pTRE (pTRE-Bax). pTet-On was transfected into DLD-1 cells using Lipofectamine (Life Technologies, Rockville, MD) and stable transfectants (DLD-1-pTet-On) were selected in RPMI-1640 medium containing 0.8 mg/ ml G418 (Life Technologies) for more than 4 weeks. pTRE-Bax and pTK-Hyg, which contains hygromycinresistance gene, were combined in a ratio of twenty to one and ethanol-precipitated. DLD-1-pTet-On cells were transfected with pTRE-Bax/pTK-Hyg, and stable transfectants were selected in RPMI-1640 medium containing 0.4 mg/ ml hygromycin (Sigma, St. Louis, MO). Western blotting Total cellular protein was extracted with NP-40-based lysis buffer and analyzed by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as described previously. 19) After having been transferred to an Immobilon membrane (Millipore, Bedford, MA), the proteins were incubated overnight with antibodies against Bax (N-20) (Santa Cruz Biotechnology, Santa Cruz, CA), caspase 3 (Santa Cruz), cytochrome c (Pharmingen, San Diego, CA), Bcl-2 (DAKO A/S, Denmark), Bcl-X (Santa Cruz) and β-actin (AC-15) (Sigma). The levels of protein were analyzed using the enhanced chemiluminescence system (Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, England) according to the manufacturer's instructions. To detect the release of cytochrome c from mitochondria, cytosol fraction was extracted with mannitol-based lysis buffer, 20) and the mitochondria-containing fraction was extracted from the pellet with NP-40-based lysis buffer. 19) Flow cytometry To quantitate apoptotic cells, an apoptosis detection system (fluorescein) (Promega, Madison, WI) was used according to the manufacturer's instructions. This system measures the fragmented DNA of apoptotic cells and is called terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assay. 
RESULTS

Establishment of a stable cell line transfected with TetOn system
To evaluate apoptosis induced by Bax overexpression in DLD-1 colon cancer in the absence of any cytotoxic signals, a stable cell line (mixed population of stable transfectants), DLD-1-pTet-On/pTRE-Bax/pTK-Hyg (DLD-1-Bax), was established. Detection of apoptosis and western blotting after induction of Bax TUNEL-positive cells increased after exposure to 1 µg/ml doxycycline and the highest percentages of TUNEL-positive cells were observed at the 36 h and 48 h time points (Fig. 1) . Continuous exposure of these cells to 1 µg/ml doxycycline did not result in total cell death but resulted in establishment of Bax-overexpressing stable cell lines (data not shown). Western blotting using whole cell fraction revealed Bax induction ( Fig.  2A ) and caspase-3 activation ( Fig. 2A ) 36 h after exposure to doxycycline. Bcl-2 protein expression did not show any change and Bcl-XL was slightly elevated 36-48 h after exposure to doxycycline ( Fig. 2A) . Bax induction was observed in both cytosol and mitochondria-containing fractions (Fig. 2B) . Cytochrome c release from mitochondria to cytosol was detected 36 h after exposure to doxycycline. Apoptosis induced by chemotherapeutic agents Concentrations of anticancer agents used in this study are based on previous reports, 7, 9) ten times higher concentrations than the maximum plasma levels in clinical use and preliminary dose-setting experiments. DLD-1-Bax cells with or without Bax induction were treated with a chemotherapeutic agent, 25 µg/ml 5-fluorouracil, 2 µg/ml mitomycin C, 1 µg/ml paclitaxel, 1 µg/ml doxorubicin, or 10 µg/ml cisplatin, and apoptosis was evaluated by TUNEL assay (Fig. 3) . In the preliminary experiments, DLD-1-Bax cells were incubated with 1 µg/ml doxycycline 6 h or 24 h before addition of chemotherapeutic agents, but there was no difference in apoptosis between 6 h and 24 h. Therefore, 1 µg/ml doxycycline was added 6 h before chemotherapeutic agent treatments. Four or five days after treatment with chemotherapeutic agents, more-than-additive numbers of apoptotic cells were observed in chemotherapeutic agent-treated DLD-1-Bax cells with Bax overexpression compared with those lacking Bax induction (Fig. 3) .
DISCUSSION
It has been reported that Bax induction alone induces apoptosis in Jurkat cells, 5) but Jurkat cells have a Bax gene mutation and do not express Bax protein. 6) Cancer cells express different levels of proapoptotic Bax protein.
6) The present study demonstrated that Bax induction alone initiated cytochrome c release from mitochondria, activation of caspase 3 and apoptosis to some extent in DLD-1 cells, which originally express a high level of proapoptotic Bax protein. Recently, a pathway between Bax induction and caspase-3 activation has been reported. Overexpressed Bax moves to mitochondria 21) and induces cytochrome c release from mitochondria. 20, 22) Released cytochrome c binds to Apaf-1 and caspase-9, and the complex subsequently activates caspase-3. 23, 24) The release of cytochrome c occurs independently of changes of mitochondrial membrane potential 20, 25) and caspase activation 20, 22) and is inhibited by Bcl-XL. 20, 26) In the present study, after Bax induction, Bcl-XL, one of the antagonists of Bax, was slightly elevated, which might alleviate the Bax-induced apoptosis in DLD-1 cells. Cytochrome c release was observed at the same time as caspase-3 activation, supporting the sequential activation of the apoptotic cascade already described. [20] [21] [22] [23] [24] We have recently shown that Bax overexpression sensitizes KATO-III gastric cancer cells to chemotherapeutic agent-induced apoptosis through enhancing the release of cytochrome c from mitochondria. 27) In the present study, apoptosis induced by all chemotherapeutic agents tested was enhanced by Bax overexpression, suggesting that the target of Bax overexpression is the final common pathway. It has been reported that dimerization of mitochondrial Bax is also associated with increased drug response in Bax-transfected human head and neck squamous cancer cells. 28) On the other hand, Strobel et al. reported that intracellular accumulation of paclitaxel was enhanced by Bax overexpression. 29) We assume that enhancement of chemotherapeutic agentinduced apoptosis by Bax overexpression is mediated both by the common pathway of mitochondrial cytochrome c release and by the specific mechanism of each chemotherapeutic agent.
It has been reported that wild-type p53 does not induce apoptosis in wild-type p53-bearing cancer cells. The present study showed that overexpression of Bax itself induced apoptosis in DLD-1 colon cancer cells to some extent, and that Bax overexpression sensitizes DLD-1 cells to chemotherapeutic agent-induced apoptosis. In the case of 5-fluorouracil, which is a key drug in the treatment of colorectal cancer, 10) enhancement of apoptosis by Bax was observed at an early time. Thus, Bax overexpression-based gene therapy may be an effective approach for the treatment of colon cancer, in combination with chemotherapy.
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